Professional Documents
Culture Documents
Biomarker
Biomarker
Members
Dr. S.Selvasubramanian, Professor, Dept. of
Veterinary Pharmacology and Toxicology, MVC,
Chennai
Dr.P.S.L.Sesh, Assistant Professor, Dept. o
VeterinaryBiochemistry, MVC, Chennai
“A biomarker is a substance used as an
indicator of a biologic state”.
Dr. Jaikanth
High cardiac specificity
Pharmacokinetics of cardiac biomarker
Easy diagnosis
Marker should play a designed role in the treatment
and management of clinical subject
1954 - SGOT (AST)
1955 - LDH
1960 - CPK
1972 - CPK isoforms by Electrophoresis
1975 - CK - MB by immunoinhibition
1975 - Myoglobin
1985 - CK - MB Mass immunoassay
1989 - Troponin T
1992 - Troponin I
Biomarkers of myocardial injury
› markers of myocardial necrosis
› markers of myocardial ischemia
Dr. Jaikanth
Zones of Ischemia Injury and Infarction with
Transmural and Subendocardial Infarction
Creatine kinase (CK/CPK) is an enzyme expressed in a
number of tissues.
Timing:
› Earliest Rise: 1-3 hrs
› Peak 6-9 hrs
› Return to normal: 12 hrs
Acute myocardial infarction
Negative predictor of MI
DRAWBACKS
• Troponin T
› 99th percentile limits - 0.01 ng/mL
› assay ranges - 0.01-25 ng/mL
(Troponin I)
› 99th percentile limits -0.04 ng/mL
› assay range -0.04-40 ng/mL
Conclusion
FDA in 2010 has approved a multimarker approach
for using the combination of ECG, the cTnI, and the
IMA levels achieving a sensitivity of 95% for ACS
Heart-type fatty acid binding protein (H-FABP)
Cardiodetect
Dr. Jaikanth
The natriuretic peptides (NP) are a group of
structurally similar but genetically distinct
peptides.
NPR-C
They lack the guanyl cyclase domain and may influence
the target cell function through inhibitory guanine
nucleotide (Gi) protein, and they likely also act as clearance
receptors for circulating peptides.
NPR-A and NPR-B
NPR- A is the most abundant type in
large blood vessels
NPR-B predominate in the brain
Both receptors are present in the
adrenal glands and the kidney
Affinity
for NPR-A : ANP > BNP > CNP
for NPR-B : CNP > BNP > ANP
Action of Atrial Natriuretic Peptide at Target Cells
ANP and BNP concentrations increase in
response to volume expansion and pressure
overload of the heart
Endopeptidase
Bnp cut point was fixed at 100pg/ml and it showed 90% sensitivity and 80%
specificity for diagnosing heart failure
Veterinary field
Chronic left ventricular systolic and diastolic dysfunction
R I S S
D S
M S
K G
R L
G G H
F R
S C R
C S K V L
G
S P K M V Q G S
32 amino acid sequence
Recombinant technology using E-co
NOTE: hBNP affects assay for BNP, but can still use proBNP or one of the proANP assays
C-reactive protein
Myeloperoxidase
Homocysteine
CRP is an acute-phase protein produced by
the liver
Industry and FDA staff guidelines 2005 had given clinical cut
off value as less than 1 mg/l as safe levels with hs-CRP
tests
Dr. Jaikanth
Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in
pathophysiology and management. Circulation 2000;102:1718-23.
Hulsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term
prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998;32:1695-700.
Latini R, Masson S, Anand I, et al. Thecomparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled
in Val-HeFT. Eur Heart J 2004;25:292-9.
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of
spironolactone therapy in patients with congestive heart failure insights from the Randomized Aldactone
Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes.
Circulation. In press.
Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003; 108:250
–252.
Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1–11.
Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf
RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non–ST-elevation acute coronary syndrome.
Circulation. 2007;115:962–971.
Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999;130:933–937.
Halldorsdottir AM, Stoker J, Porche-Sorbet R, Eby CS. Soluble CD40 ligand measurement inaccuracies attributable to specimen type,
processing time, and ELISA method. Clin Chem. 2005;51:1054 –1057.
The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Myocardial
infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the
Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36: 959–969.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other
circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397.
Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA,
Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non–ST-elevation
myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative
Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004;109:580 –586.
Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928 –935.
James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons ML, Topol EJ, Venge P, Wallentin L. Troponin and C-reactive
protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J
Am Coll Cardiol. 2003;41:916 –924.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin
therapy. N Engl J Med. 2005;352:20 –28.
Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach
to risk stratification in non–ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type
natriuretic peptide. Circulation. 2002;105:1760 –1763.
Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations
of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new
immunoradiometric sandwich assay. Clin Chem. 2007;53:284 –291.